1
|
de Matos RRC, Ferreira GM, Bonecker S, Rouxinol M, da Costa ES, Mello FV, Abdelhay E, Ribeiro RC, Zalcberg I, Silva MLM. BCR- ABL1 co-occurring with CBFA2T3- GLIS2 and RAM immunophenotype in a non-Down syndrome infant with acute megakaryoblastic leukemia. Leuk Lymphoma 2023; 64:2042-2046. [PMID: 37548333 DOI: 10.1080/10428194.2023.2243532] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/10/2023] [Accepted: 07/22/2023] [Indexed: 08/08/2023]
Affiliation(s)
- Roberto R Capela de Matos
- Department of Cytogenetics and Molecular Biology, Bone Marrow Transplantation Unit, and Post Graduation Program in Oncology, Instituto Nacional de Câncer José de Alencar Gomes da Silva (INCA), Rio de Janeiro, Brazil
| | - Gerson Moura Ferreira
- Department of Cytogenetics and Molecular Biology, Bone Marrow Transplantation Unit, and Post Graduation Program in Oncology, Instituto Nacional de Câncer José de Alencar Gomes da Silva (INCA), Rio de Janeiro, Brazil
| | - Simone Bonecker
- Department of Cytogenetics and Molecular Biology, Bone Marrow Transplantation Unit, and Post Graduation Program in Oncology, Instituto Nacional de Câncer José de Alencar Gomes da Silva (INCA), Rio de Janeiro, Brazil
| | | | - Elaine Sobral da Costa
- Clinical Medicine Post-Graduation Program, Faculty of Medicine, and Pediatrics Institute IPPMG, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil
| | - Fabiana V Mello
- Clinical Medicine Post-Graduation Program, Faculty of Medicine, and Pediatrics Institute IPPMG, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil
| | - Eliana Abdelhay
- Department of Cytogenetics and Molecular Biology, Bone Marrow Transplantation Unit, and Post Graduation Program in Oncology, Instituto Nacional de Câncer José de Alencar Gomes da Silva (INCA), Rio de Janeiro, Brazil
| | - Raul C Ribeiro
- Department of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA
| | - Ilana Zalcberg
- Department of Cytogenetics and Molecular Biology, Bone Marrow Transplantation Unit, and Post Graduation Program in Oncology, Instituto Nacional de Câncer José de Alencar Gomes da Silva (INCA), Rio de Janeiro, Brazil
| | - Maria Luiza Macedo Silva
- Department of Cytogenetics and Molecular Biology, Bone Marrow Transplantation Unit, and Post Graduation Program in Oncology, Instituto Nacional de Câncer José de Alencar Gomes da Silva (INCA), Rio de Janeiro, Brazil
| |
Collapse
|
2
|
Ling T, Lang WH, Maier J, Quintana Centurion M, Rivas F. Cytostatic and Cytotoxic Natural Products against Cancer Cell Models. Molecules 2019; 24:molecules24102012. [PMID: 31130671 PMCID: PMC6571673 DOI: 10.3390/molecules24102012] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/29/2019] [Revised: 05/24/2019] [Accepted: 05/24/2019] [Indexed: 12/20/2022] Open
Abstract
The increasing prevalence of drug resistant and/or high-risk cancers indicate further drug discovery research is required to improve patient outcome. This study outlines a simplified approach to identify lead compounds from natural products against several cancer cell lines, and provides the basis to better understand structure activity relationship of the natural product cephalotaxine. Using high-throughput screening, a natural product library containing fractions and pure compounds was interrogated for proliferation inhibition in acute lymphoblastic leukemia cellular models (SUP-B15 and KOPN-8). Initial hits were verified in control and counter screens, and those with EC50 values ranging from nanomolar to low micromolar were further characterized via mass spectrometry, NMR, and cytotoxicity measurements. Most of the active compounds were alkaloid natural products including cephalotaxine and homoharringtonine, which were validated as protein synthesis inhibitors with significant potency against several cancer cell lines. A generated BODIPY-cephalotaxine probe provides insight into the mode of action of cephalotaxine and further rationale for its weaker potency when compared to homoharringtonine. The steroidal natural products (ecdysone and muristerone A) also showed modest biological activity and protein synthesis inhibition. Altogether, these findings demonstrate that natural products continue to provide insight into structure and function of molecules with therapeutic potential against drug resistant cancer cell models.
Collapse
Affiliation(s)
- Taotao Ling
- Department of Chemical Biology and Therapeutics, St. Jude Children's Research Hospital. 262 Danny Thomas Place. Memphis, TN 38105-3678, USA.
| | - Walter H Lang
- Department of Chemical Biology and Therapeutics, St. Jude Children's Research Hospital. 262 Danny Thomas Place. Memphis, TN 38105-3678, USA.
| | - Julie Maier
- Department of Chemical Biology and Therapeutics, St. Jude Children's Research Hospital. 262 Danny Thomas Place. Memphis, TN 38105-3678, USA.
| | - Marizza Quintana Centurion
- Dirección de Investigación Biológica/Museo Nacional de Historia Natural del Paraguay, Casilla de Correo 19.004. Sucursal 1, Campus UNA. 169 CDP San Lorenzo, Central XI, Paraguay.
| | - Fatima Rivas
- Department of Chemical Biology and Therapeutics, St. Jude Children's Research Hospital. 262 Danny Thomas Place. Memphis, TN 38105-3678, USA.
| |
Collapse
|
3
|
Zhang X, Guo X. Coexistence of BCR/ABL1 p190 transcript and CEBPA double mutations in de novo acute myeloid leukemia. Leuk Lymphoma 2019; 60:2844-2846. [PMID: 31050567 DOI: 10.1080/10428194.2019.1608532] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
Affiliation(s)
- Xueya Zhang
- Department of Hematology, The Second Affiliated Hospital of Fujian Medical University, Quanzhou, China
| | - Xizhe Guo
- Department of Hematology, The Second Affiliated Hospital of Fujian Medical University, Quanzhou, China
| |
Collapse
|
4
|
Pérard-Viret J, Quteishat L, Alsalim R, Royer J, Dumas F. Cephalotaxus Alkaloids. THE ALKALOIDS. CHEMISTRY AND BIOLOGY 2017; 78:205-352. [PMID: 28838429 PMCID: PMC7110560 DOI: 10.1016/bs.alkal.2017.07.001] [Citation(s) in RCA: 22] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
Cephalotaxus alkaloids represent a family of plant secondary metabolites known for 60 years. Significant activity against leukemia in mice was demonstrated for extracts of Cephalotaxus. Cephalotaxine (CET) (1), the major alkaloid of this series was isolated from Cephalotaxus drupacea species by Paudler in 1963. The subsequent discovery of promising antitumor activity among new Cephalotaxus derivatives reported by Chinese, Japanese, and American teams triggered extensive structure elucidation and biological studies in this family. The structural feature of this cephalotaxane family relies mainly on its tetracyclic alkaloid backbone, which comprises an azaspiranic 1-azaspiro[4.4]nonane unit (rings C and D) and a benzazepine ring system (rings A and B), which is linked by its C3 alcohol function to a chiral oxygenated side chain by a carboxylic function alpha to a tetrasubstituted carbon center. The botanical distribution of these alkaloids is limited to the Cephalotaxus genus (Cephalotaxaceae). The scope of biological activities of the Cephalotaxus alkaloids is mainly centered on the antileukemic activity of homoharringtonine (HHT) (2), which in particular demonstrated marked benefits in the treatment of orphan myeloid leukemia and was approved as soon as 2009 by European Medicine Agency and by US Food and Drug Administration in 2012. Its exact mechanism of action was partly elucidated and it was early recognized that HHT (2) inhibited protein synthesis at the level of the ribosome machinery. Interestingly, after a latency period of two decades, the topic of Cephalotaxus alkaloids reemerged as a prolific source of new natural structures. To date, more than 70 compounds have been identified and characterized. Synthetic studies also regained attention during the past two decades, and numerous methodologies were developed to access the first semisynthetic HHT (2) of high purity suitable for clinical studies, and then high grade enantiomerically pure CET (1), HHT (2), and analogs.
Collapse
Affiliation(s)
- Joëlle Pérard-Viret
- Université Paris Descartes, CNRS, Université Sorbonne Paris Cité, Paris, France
| | - Laith Quteishat
- Université Paris Sud, CNRS, Université Paris Saclay, Châtenay-Malabry, France
| | - Rana Alsalim
- Université Paris Sud, CNRS, Université Paris Saclay, Châtenay-Malabry, France
| | - Jacques Royer
- Université Paris Descartes, CNRS, Université Sorbonne Paris Cité, Paris, France
| | - Françoise Dumas
- Université Paris Sud, CNRS, Université Paris Saclay, Châtenay-Malabry, France
| |
Collapse
|